Jenthera Patents

Patent portfolio assigned to Jenthera (verified via public assignee records). Estimated patent count: 1. Montreal preclinical in-vivo CRISPR (direct ribonucleoprotein delivery) gene-editing company for oncology. Strategic R&D collaboration with Future Fields (protein production). Patent WO2024031187A1 filed by Jenthera Therapeutics. No paying customers (preclinical biotech).